[
      {
        "id": 1,
        "name": "5-Amino-1MQ",
        "abbreviation": "5",
        "short_description": "NNMT Inhibitor | Longevity & Metabolic Enhancement",
        "research_level": "Limited Research",
        "tags": ["Longevity & Life Extension", "Metabolism Support", "Weight Loss"],
        "common_research_uses": ["NAD+ Enhancement", "Mitochondrial Function", "Cellular Repair", "Energy Metabolism", "Insulin Sensitivity"],
        "typical_dose": "50-100mg",
        "typical_dose_frequency": "1x daily",
        "route_of_administration": [
          {
            "route": "Oral",
            "details": "N/A - Oral administration"
          }
        ],
        "cycle": "8-12 weeks",
        "storage": {
          "temperature": "Room temperature",
          "condition": "Refrigerated"
        },
        "overview": {
          "what_is_it": "5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular NAD+ levels and mitochondrial function. Originally developed for metabolic research, it's gaining attention for its potential anti-aging properties and ability to improve energy metabolism at the cellular level.",
          "key_benefits": ["Enhanced NAD+ levels", "improved mitochondrial function", "longevity benefits", "better energy metabolism", "enhanced cellular repair", "improved insulin sensitivity", "convenient daily dosing"],
          "mechanism_of_action": "Orally administered 5-Amino-1MQ inhibits NNMT enzyme systemically, preventing NAD+ degradation and maintaining higher cellular NAD+ levels throughout the body, supporting mitochondrial function and metabolic processes"
        },
        "research_indications": {
          "longevity": {
            "effectiveness": "Most Effective",
            "categories": [{
                "title": "NAD+ Enhancement",
                "description": "Significantly increases cellular NAD+ levels by inhibiting NNMT enzyme, supporting cellular energy production and DNA repair mechanisms essential for healthy aging"
            }, {
                "title": "Mitochondrial Function",
                "description": "Improves mitochondrial biogenesis and efficiency, enhancing cellular energy production and reducing oxidative stress markers associated with aging"
            }, {
                "title": "Cellular Repair",
                "description": "Enhanced NAD+ availability supports sirtuins and other longevity pathways involved in DNA repair, cellular maintenance, and stress resistance"
            }]
          },
          "metabolism": {
            "effectiveness": "Effective",
            "categories": [
                {
                    "title": "Energy Metabolism",
                    "description": "Improves cellular energy production through enhanced mitochondrial function and more efficient glucose and fatty acid utilization pathways"
                },
                {
                    "title": "Insulin Sensitivity",
                    "description": "Research shows improved insulin sensitivity and glucose metabolism through enhanced cellular energy processes and mitochondrial function"
                },
                {
                    "title": "Metabolic Flexibility",
                    "description": "Enhances the body's ability to switch between fuel sources (glucose and fat) for optimal energy production and metabolic health"
                }
            ]
          },
          "weight_loss": {
            "effectiveness": "Moderate",
            "categories": [
                {
                    "title": "Metabolic Rate Enhancement",
                    "description": "Increases basal metabolic rate and helps body burn fat for energy while maintaining muscle mass through improved mitochondrial function"
                },
                {
                    "title": "Fat Oxidation",
                    "description": "Studies show enhanced fat burning capacity and improved body composition through optimized cellular energy metabolism"
                },
                {
                    "title": "Appetite Regulation",
                    "description": "May help regulate appetite and energy balance through improved cellular signaling and metabolic efficiency"
                }
            ]
          }
        },
        "research_protocols": [
          {
            "goal": "Conservative approach",
            "dose": "25mg",
            "frequency": "1x daily",
            "route": "Oral (with food)"
          },
          {
            "goal": "Standard starting dose",
            "dose": "50mg",
            "frequency": "1x daily",
            "route": "Oral (with food)"
          },
          {
            "goal": "Typical maintenance",
            "dose": "75mg",
            "frequency": "1x daily",
            "route": "Oral (with food)"
          },
          {
            "goal": "Maximum dose",
            "dose": "100mg",
            "frequency": "1x daily",
            "route": "Oral (with food)"
          },
          {
            "goal": "Split dosing option",
            "dose": "50mg",
            "frequency": "2x daily",
            "route": "Oral (with meals)"
          }
        ],
        "protocol_timing": "Take 5-Amino-1MQ with food to improve absorption and reduce potential GI effects. Consistent daily timing helps maintain steady NAD+ levels. Morning or early afternoon dosing is preferred to avoid potential sleep interference.",
        "peptide_interactions": [
          {
            "peptide": "NAD+ Precursors (NMN, NR)",
            "interaction": "Synergistic",
            "description": "May work synergistically with NAD+ precursors by preventing breakdown while supporting production"
          },
          {
            "peptide": "Resveratrol",
            "interaction": "Synergistic",
            "description": "Both support longevity pathways; resveratrol activates sirtuins while 5-Amino-1MQ provides NAD+ substrate"
          },
          {
            "peptide": "Metformin",
            "interaction": "Monitor Combination",
            "description": "Both affect metabolic pathways; combination may enhance effects but requires careful monitoring"
          },
          {
            "peptide": "BPC-157",
            "interaction": "Compatible",
            "description": "No known interactions; different mechanisms of action with potential complementary benefits"
          },
          {
            "peptide": "Blood Thinners",
            "interaction": "Unknown",
            "description": "Limited interaction data; consult healthcare provider before combining with anticoagulants"
          },
          {
            "peptide": "Berberine",
            "interaction": "Monitor Combination",
            "description": "Both affect metabolic pathways; potential additive effects on glucose metabolism"
          }
        ],
        "reconstitution_steps": [
          {
            "step": 1,
            "instruction": "Use pre-made capsules for convenience and accuracy (recommended)"
          },
          {
            "step": 2,
            "instruction": "If using powder: measure precise dose with milligram scale"
          },
          {
            "step": 3,
            "instruction": "Take with food to improve absorption and reduce GI effects"
          },
          {
            "step": 4,
            "instruction": "Maintain consistent daily timing for optimal results"
          },
          {
            "step": 5,
            "instruction": "Store in cool, dry place away from light and moisture"
          },
          {
            "step": 6,
            "instruction": "Consider cycling: 8-12 weeks on, 2-4 weeks off"
          }
        ],
        "quality_indicators": {
          "positive": [
            {
              "indicator": "White to off-white capsules",
              "description": "High-quality capsules should be uniform in color and size with clear labeling and batch information"
            },
            {
              "indicator": "Third-party testing certificates",
              "description": "Reputable suppliers provide COA with purity analysis (should be >98% pure) and heavy metal testing"
            },
            {
              "indicator": "Proper pharmaceutical packaging",
              "description": "Sealed bottles with moisture protection, clear expiration dates, and professional labeling"
            }
          ],
          "negative": [
            {
              "indicator": "Moisture damage or clumping",
              "description": "Capsules should not be sticky, discolored, or show signs of moisture exposure or heat damage"
            },
            {
              "indicator": "Unusual odor or appearance",
              "description": "Should be relatively odorless; strong chemical odors may indicate contamination or degradation"
            }
          ]
        },
        "what_to_expect": [
          "Week 1-2: Gradual increase in energy levels and mental clarity",
          "Week 2-4: Enhanced exercise performance and recovery",
          "Week 4-8: Improved metabolic markers and body composition",
          "Week 8-12: Sustained longevity benefits and cellular health",
          "Side effects: Generally minimal, occasional mild GI adjustment",
          "Most effective for: Metabolic health, longevity, energy enhancement"
        ],
        "side_effects_and_safety": [
          "No human clinical trials published - all dosing extrapolated from animal studies",
          "38.4% oral bioavailability demonstrated in rats (PubMed 34304009)",
          "Start with lowest effective dose (25-50mg) to assess tolerance",
          "Take with food to reduce potential GI effects",
          "Monitor for any unusual symptoms and discontinue if adverse effects occur",
          "Not recommended for pregnant or breastfeeding women",
          "Consult healthcare provider before use, especially with existing conditions"
        ],
        "references": [
          {
            "title": "Mouse Obesity Study - Neelakantan et al. (2018)",
            "type": "Animal study",
            "dose_info": "20mg/kg TID (60mg/kg/day)",
            "duration": "11 days",
            "sample_size": "n=10 mice/group",
            "findings": "Diet-induced obese mice showed 5.1% weight loss, 30% adipocyte size reduction. Human equivalent ~5mg/kg/day using FDA allometric scaling.",
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5826726/"
          },
          {
            "title": "Rat Pharmacokinetics Study (2021)",
            "type": "Animal PK study",
            "dose_info": "Various doses",
            "duration": "Bioavailability",
            "findings": "Demonstrated 38.4% oral bioavailability, half-life 6.9hr (oral) and 3.8hr (IV). Supports oral administration viability.",
            "url": "https://pubmed.ncbi.nlm.nih.gov/34304009/"
          },
          {
            "title": "Muscle Function in Aged Mice (2024)",
            "type": "Animal study",
            "dose_info": "10mg/kg/day SubQ",
            "duration": "8 weeks",
            "findings": "40% grip strength improvement in sedentary mice, 60% with exercise. No adverse effects observed.",
            "url": "https://www.nature.com/articles/s41598-024-66034-9"
          }
        ],
        "quick_start_guide": {
            "typical_dose": "50-75mg",
            "how_often": "Once daily with food",
            "how_to_take": "N/A - Oral administration",
            "best_timing": "With breakfast or lunch for better absorption",
            "effects_timeline": "Energy: 1-2 weeks, Metabolic: 4-8 weeks, Longevity: 8-12 weeks",
            "storage": "Cool, dry place at room temperature",
            "cycle_length": "8-12 weeks",
            "break_between": "2-4 weeks off between cycles"
        }
      },
    ]

[  
    {
        "name": "5-Amino-1MQ",
        "typical_dose": "50-100mg",
        "typical_dose_frequency": "1x daily",
        "route_of_administration": [
          {
            "route": "Oral",
            "details": "N/A - Oral administration"
          }
        ],
        "cycle": "8-12 weeks",
        "storage": {
          "temperature": "Room temperature",
          "condition": "Refrigerated"
        },
        "overview": {
          "what_is_it": "5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular NAD+ levels and mitochondrial function. Originally developed for metabolic research, it's gaining attention for its potential anti-aging properties and ability to improve energy metabolism at the cellular level.",
          "key_benefits": ["Enhanced NAD+ levels", "improved mitochondrial function", "longevity benefits", "better energy metabolism", "enhanced cellular repair", "improved insulin sensitivity", "convenient daily dosing"],
          "mechanism_of_action": "Orally administered 5-Amino-1MQ inhibits NNMT enzyme systemically, preventing NAD+ degradation and maintaining higher cellular NAD+ levels throughout the body, supporting mitochondrial function and metabolic processes"
        },
        "research_indications": {
          "longevity": {
            "effectiveness": "Most Effective",
            "categories": [{
                "title": "NAD+ Enhancement",
                "description": "Significantly increases cellular NAD+ levels by inhibiting NNMT enzyme, supporting cellular energy production and DNA repair mechanisms essential for healthy aging"
            }, {
                "title": "Mitochondrial Function",
                "description": "Improves mitochondrial biogenesis and efficiency, enhancing cellular energy production and reducing oxidative stress markers associated with aging"
            }, {
                "title": "Cellular Repair",
                "description": "Enhanced NAD+ availability supports sirtuins and other longevity pathways involved in DNA repair, cellular maintenance, and stress resistance"
            }]
          },
          "metabolism": {
            "effectiveness": "Effective",
            "categories": [
                {
                    "title": "Energy Metabolism",
                    "description": "Improves cellular energy production through enhanced mitochondrial function and more efficient glucose and fatty acid utilization pathways"
                },
                {
                    "title": "Insulin Sensitivity",
                    "description": "Research shows improved insulin sensitivity and glucose metabolism through enhanced cellular energy processes and mitochondrial function"
                },
                {
                    "title": "Metabolic Flexibility",
                    "description": "Enhances the body's ability to switch between fuel sources (glucose and fat) for optimal energy production and metabolic health"
                }
            ]
          },
          "weight_loss": {
            "effectiveness": "Moderate",
            "categories": [
                {
                    "title": "Metabolic Rate Enhancement",
                    "description": "Increases basal metabolic rate and helps body burn fat for energy while maintaining muscle mass through improved mitochondrial function"
                },
                {
                    "title": "Fat Oxidation",
                    "description": "Studies show enhanced fat burning capacity and improved body composition through optimized cellular energy metabolism"
                },
                {
                    "title": "Appetite Regulation",
                    "description": "May help regulate appetite and energy balance through improved cellular signaling and metabolic efficiency"
                }
            ]
          }
        },
        "research_protocols": [
          {
            "goal": "Conservative approach",
            "dose": "25mg",
            "frequency": "1x daily",
            "route": "Oral (with food)"
          },
          {
            "goal": "Standard starting dose",
            "dose": "50mg",
            "frequency": "1x daily",
            "route": "Oral (with food)"
          },
          {
            "goal": "Typical maintenance",
            "dose": "75mg",
            "frequency": "1x daily",
            "route": "Oral (with food)"
          },
          {
            "goal": "Maximum dose",
            "dose": "100mg",
            "frequency": "1x daily",
            "route": "Oral (with food)"
          },
          {
            "goal": "Split dosing option",
            "dose": "50mg",
            "frequency": "2x daily",
            "route": "Oral (with meals)"
          }
        ],
        "protocol_timing": "Take 5-Amino-1MQ with food to improve absorption and reduce potential GI effects. Consistent daily timing helps maintain steady NAD+ levels. Morning or early afternoon dosing is preferred to avoid potential sleep interference.",
        "peptide_interactions": [
          {
            "peptide": "NAD+ Precursors (NMN, NR)",
            "interaction": "Synergistic",
            "description": "May work synergistically with NAD+ precursors by preventing breakdown while supporting production"
          },
          {
            "peptide": "Resveratrol",
            "interaction": "Synergistic",
            "description": "Both support longevity pathways; resveratrol activates sirtuins while 5-Amino-1MQ provides NAD+ substrate"
          },
          {
            "peptide": "Metformin",
            "interaction": "Monitor Combination",
            "description": "Both affect metabolic pathways; combination may enhance effects but requires careful monitoring"
          },
          {
            "peptide": "BPC-157",
            "interaction": "Compatible",
            "description": "No known interactions; different mechanisms of action with potential complementary benefits"
          },
          {
            "peptide": "Blood Thinners",
            "interaction": "Unknown",
            "description": "Limited interaction data; consult healthcare provider before combining with anticoagulants"
          },
          {
            "peptide": "Berberine",
            "interaction": "Monitor Combination",
            "description": "Both affect metabolic pathways; potential additive effects on glucose metabolism"
          }
        ],
        "reconstitution_steps": [
          {
            "step": 1,
            "instruction": "Use pre-made capsules for convenience and accuracy (recommended)"
          },
          {
            "step": 2,
            "instruction": "If using powder: measure precise dose with milligram scale"
          },
          {
            "step": 3,
            "instruction": "Take with food to improve absorption and reduce GI effects"
          },
          {
            "step": 4,
            "instruction": "Maintain consistent daily timing for optimal results"
          },
          {
            "step": 5,
            "instruction": "Store in cool, dry place away from light and moisture"
          },
          {
            "step": 6,
            "instruction": "Consider cycling: 8-12 weeks on, 2-4 weeks off"
          }
        ],
        "quality_indicators": {
          "positive": [
            {
              "indicator": "White to off-white capsules",
              "description": "High-quality capsules should be uniform in color and size with clear labeling and batch information"
            },
            {
              "indicator": "Third-party testing certificates",
              "description": "Reputable suppliers provide COA with purity analysis (should be >98% pure) and heavy metal testing"
            },
            {
              "indicator": "Proper pharmaceutical packaging",
              "description": "Sealed bottles with moisture protection, clear expiration dates, and professional labeling"
            }
          ],
          "negative": [
            {
              "indicator": "Moisture damage or clumping",
              "description": "Capsules should not be sticky, discolored, or show signs of moisture exposure or heat damage"
            },
            {
              "indicator": "Unusual odor or appearance",
              "description": "Should be relatively odorless; strong chemical odors may indicate contamination or degradation"
            }
          ]
        },
        "what_to_expect": [
          "Week 1-2: Gradual increase in energy levels and mental clarity",
          "Week 2-4: Enhanced exercise performance and recovery",
          "Week 4-8: Improved metabolic markers and body composition",
          "Week 8-12: Sustained longevity benefits and cellular health",
          "Side effects: Generally minimal, occasional mild GI adjustment",
          "Most effective for: Metabolic health, longevity, energy enhancement"
        ],
        "side_effects_and_safety": [
          "No human clinical trials published - all dosing extrapolated from animal studies",
          "38.4% oral bioavailability demonstrated in rats (PubMed 34304009)",
          "Start with lowest effective dose (25-50mg) to assess tolerance",
          "Take with food to reduce potential GI effects",
          "Monitor for any unusual symptoms and discontinue if adverse effects occur",
          "Not recommended for pregnant or breastfeeding women",
          "Consult healthcare provider before use, especially with existing conditions"
        ],
        "references": [
          {
            "title": "Mouse Obesity Study - Neelakantan et al. (2018)",
            "type": "Animal study",
            "dose_info": "20mg/kg TID (60mg/kg/day)",
            "duration": "11 days",
            "sample_size": "n=10 mice/group",
            "findings": "Diet-induced obese mice showed 5.1% weight loss, 30% adipocyte size reduction. Human equivalent ~5mg/kg/day using FDA allometric scaling.",
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5826726/"
          },
          {
            "title": "Rat Pharmacokinetics Study (2021)",
            "type": "Animal PK study",
            "dose_info": "Various doses",
            "duration": "Bioavailability",
            "findings": "Demonstrated 38.4% oral bioavailability, half-life 6.9hr (oral) and 3.8hr (IV). Supports oral administration viability.",
            "url": "https://pubmed.ncbi.nlm.nih.gov/34304009/"
          },
          {
            "title": "Muscle Function in Aged Mice (2024)",
            "type": "Animal study",
            "dose_info": "10mg/kg/day SubQ",
            "duration": "8 weeks",
            "findings": "40% grip strength improvement in sedentary mice, 60% with exercise. No adverse effects observed.",
            "url": "https://www.nature.com/articles/s41598-024-66034-9"
          }
        ],
        "quick_start_guide": {
            "typical_dose": "50-75mg",
            "how_often": "Once daily with food",
            "how_to_take": "N/A - Oral administration",
            "best_timing": "With breakfast or lunch for better absorption",
            "effects_timeline": "Energy: 1-2 weeks, Metabolic: 4-8 weeks, Longevity: 8-12 weeks",
            "storage": "Cool, dry place at room temperature",
            "cycle_length": "8-12 weeks",
            "break_between": "2-4 weeks off between cycles"
        }
      },
      {
        "name": "5-Amino-1MQ",
        "typical_dose": "150-600mcg (injectable) or 50-100mg (oral)",
        "typical_dose_frequency": "1x daily",
        "route_of_administration": [
        {
        "route": "SubQ injectable",
        "details": "Subcutaneous injection; abdomen, thigh, or arm"
        },
        ],
        "cycle": "4-8 weeks (injectable) or 8-12 weeks (oral as per other sources)",
        "storage": {
        "temperature": "2-8°C (injectable); room temperature (oral)",
        "condition": "Refrigerated (injectable); keep sealed, dry"
        },
        "overview": {
        "what_is_it": "5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular NAD+ levels and mitochondrial function. Originally developed for metabolic research, it's gaining attention for its potential anti-aging properties and ability to improve energy metabolism at the cellular level.",
        "key_benefits": [
        "Higher bioavailability",
        "precise dosing",
        "rapid systemic effects",
        "research-validated delivery method",
        "enhanced NAD+ elevation",
        "superior metabolic impact"
        ],
        "mechanism_of_action": "Injectable 5-Amino-1MQ provides direct systemic delivery with 100% bioavailability, rapidly inhibiting NNMT enzyme and maximizing NAD+ elevation for enhanced cellular energy and metabolic benefits"
        },
        "research_indications": {
        "metabolism": {
        "effectiveness": "Most Effective",
        "categories": [
        {
        "title": "Rapid Metabolic Enhancement",
        "description": "Injectable delivery provides immediate systemic effects on metabolic rate and cellular energy production with superior bioavailability"
        },
        {
        "title": "Enhanced Fat Oxidation",
        "description": "Direct systemic delivery maximizes fat burning capacity and metabolic flexibility through optimal NNMT inhibition"
        },
        {
        "title": "Improved Glucose Metabolism",
        "description": "Injectable form shows enhanced effects on insulin sensitivity and glucose utilization compared to oral administration"
        }
        ]
        },
        "weight_loss": {
        "effectiveness": "Effective",
        "categories": [
        {
        "title": "Accelerated Fat Loss",
        "description": "Research studies using injectable 5-Amino-1MQ showed significant weight loss and body composition improvements"
        },
        {
        "title": "Metabolic Rate Boost",
        "description": "Direct systemic delivery provides maximum metabolic enhancement for weight management and body recomposition"
        },
        {
        "title": "Appetite Suppression",
        "description": "Injectable form may provide enhanced appetite regulation effects through optimized metabolic signaling"
        }
        ]
        },
        "longevity": {
        "effectiveness": "Moderate",
        "categories": [
        {
        "title": "Maximal NAD+ Enhancement",
        "description": "Injectable delivery achieves highest NAD+ levels and most pronounced longevity pathway activation"
        },
        {
        "title": "Cellular Repair Optimization",
        "description": "Superior bioavailability enhances cellular repair mechanisms and stress resistance pathways"
        },
        {
        "title": "Mitochondrial Optimization",
        "description": "Direct systemic delivery maximizes mitochondrial biogenesis and function for longevity benefits"
        }
        ]
        }
        },
        "research_protocols": [
        {
        "goal": "Conservative starting",
        "dose": "150-250mcg",
        "frequency": "1x daily",
        "route": "SubQ"
        },
        {
        "goal": "Conservative standard",
        "dose": "250-500mcg",
        "frequency": "1x daily",
        "route": "SubQ"
        },
        {
        "goal": "Conservative moderate",
        "dose": "500mcg",
        "frequency": "1x daily",
        "route": "SubQ"
        },
        {
        "goal": "Mouse study (PMC5826726)",
        "dose": "20mg/kg TID (60mg/kg/day)",
        "frequency": "3x daily",
        "route": "SubQ (mice)"
        },
        {
        "goal": "Human equivalent (FDA scaling)",
        "dose": "~5mg/kg/day (~350mg for 70kg)",
        "frequency": "theoretical",
        "route": "not tested"
        }
        ],
        "protocol_timing": "Morning or early afternoon dosing for injectables is best to avoid potential sleep interference. Rotate injection sites for safety. Oral protocols may align similarly.",
        "peptide_interactions": [
        {
        "peptide": "NAD+ Precursors (NMN, NR)",
        "interaction": "Synergistic",
        "description": "May work synergistically with NAD+ precursors by preventing breakdown while supporting production"
        },
        {
        "peptide": "Resveratrol",
        "interaction": "Synergistic",
        "description": "Both support longevity pathways; resveratrol activates sirtuins while 5-Amino-1MQ provides NAD+ substrate"
        },
        {
        "peptide": "Metformin",
        "interaction": "Monitor Combination",
        "description": "Both affect metabolic pathways; combination may enhance effects but requires careful monitoring"
        },
        {
        "peptide": "BPC-157",
        "interaction": "Compatible",
        "description": "No known interactions; different mechanisms of action with potential complementary benefits"
        },
        {
        "peptide": "Blood Thinners",
        "interaction": "Unknown",
        "description": "Limited interaction data; consult healthcare provider before combining with anticoagulants"
        },
        {
        "peptide": "Berberine",
        "interaction": "Monitor Combination",
        "description": "Both affect metabolic pathways; potential additive effects on glucose metabolism"
        }
        ],
        "reconstitution_steps": [
        {
        "step": 1,
        "instruction": "Confirm which protocol (mcg vs mg) you're following"
        },
        {
        "step": 2,
        "instruction": "Clean vial stopper, inject BAC water slowly down side"
        },
        {
        "step": 3,
        "instruction": "Gently swirl until dissolved (never shake)"
        },
        {
        "step": 4,
        "instruction": "Label clearly with concentration AND units (mg/mL)"
        },
        {
        "step": 5,
        "instruction": "Store in refrigerator, use within 28 days"
        }
        ],
        "quality_indicators": {
        "positive": [
        {
        "indicator": "Vial size matches protocol",
        "description": "5-10mg vials for conservative mcg dosing, 50-200mg vials for common mg dosing"
        },
        {
        "indicator": "Orange to amber-colored powder",
        "description": "5-Amino-1MQ commonly appears as orange to amber colored powder. Color consistency within batch is important"
        },
        {
        "indicator": "Clear solution after reconstitution",
        "description": "Should dissolve completely in BAC water to form clear, colorless solution with no particles"
        },
        {
        "indicator": "Research-grade sourcing",
        "description": "Obtained from reputable research chemical suppliers with proper documentation and purity certificates"
        }
        ],
        "negative": [
        {
        "indicator": "Clumping or moisture damage",
        "description": "Powder should not be clumped, sticky, or show signs of moisture exposure during storage"
        },
        {
        "indicator": "Cloudy reconstitution",
        "description": "Persistent cloudiness or particles after reconstitution may indicate degradation or contamination"
        }
        ]
        },
        "what_to_expect": [
        "Week 1: Energy increase (variable by protocol)",
        "Week 2-3: Metabolic changes (more pronounced with mg dosing)",
        "Week 3-4: May feel 'winded' during cardio (adaptation phase)",
        "Week 4-6: Body composition changes (dose-dependent)",
        "Week 6-8: Effects plateau - cycling recommended",
        "Conservative mcg protocol: Subtle or minimal effects reported",
        "Common mg protocol: More pronounced effects",
        "Most effective for: Unknown due to lack of human trials"
        ],
        "side_effects_and_safety": [
        "Verify dose units - mcg vs mg is 1000x difference",
        "Start with lower doses to assess tolerance",
        "Use sterile injection technique to prevent infection",
        "Not recommended for pregnant or breastfeeding women"
        ],
        "references": [
        {
        "title": "Mouse Obesity Study - Neelakantan et al. (2018)",
        "type": "Animal study",
        "dose_info": "20mg/kg TID (60mg/kg/day)",
        "duration": "11 days",
        "sample_size": "n=10 mice/group",
        "findings": "Diet-induced obese mice showed 5.1% weight loss, 30% adipocyte size reduction. Human equivalent ~5mg/kg/day using FDA allometric scaling.",
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5826726/"
        },
        {
        "title": "Rat Pharmacokinetics Study (2021)",
        "type": "Animal PK study",
        "dose_info": "Various doses",
        "duration": "Bioavailability",
        "findings": "Demonstrated 38.4% oral bioavailability, half-life 6.9hr (oral) and 3.8hr (IV). Supports oral administration viability.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/34304009/"
        },
        {
        "title": "Muscle Function in Aged Mice (2024)",
        "type": "Animal study",
        "dose_info": "10mg/kg/day SubQ",
        "duration": "8 weeks",
        "findings": "40% grip strength improvement in sedentary mice, 60% with exercise. No adverse effects observed.",
        "url": "https://www.nature.com/articles/s41598-024-66034-9"
        }
        ],
        "quick_start_guide": {
        "typical_dose": "150-600mcg (injectable) or 50-100mg (oral)",
        "how_often": "Once daily",
        "how_to_take": "SubQ abdominal, thigh, or arm (injectable); N/A for oral",
        "best_timing": "Morning or early afternoon (injectable); with food (oral)",
        "effects_timeline": "Energy: 3-7 days, Metabolic: 1-3 weeks, Weight: 2-6 weeks",
        "storage": "Refrigerate (injectable); room temp (oral)",
        "cycle_length": "4-8 weeks (injectable); 8-12 weeks (oral alternate)",
        "break_between": "2-4 weeks off between cycles"
        }
        },
        {
            "name": "Adipotide (Prohibitin-TP01)",
            "typical_dose": "0.43 mg/kg",
            "typical_dose_frequency": "Once daily",
            "route_of_administration": [
                {
                    "route": "Injectable (Subcutaneous)",
                    "details": "Rotated abdominal SubQ sites"
                }
            ],
            "cycle": "28 days",
            "storage": {
                "temperature": "2–8°C (reconstituted)",
                "condition": "Refrigerated"
            },
            "overview": {
                "what_is_it": "Adipotide (Prohibitin‑TP01) is a chimeric, adipose‑vasculature–targeted peptidomimetic that homes to prohibitin/annexin A2 on white adipose tissue endothelium and delivers a pro‑apoptotic D‑(KLAKLAK)2 motif. In obese primates it produced rapid fat loss with improved insulin resistance, but development halted after an early Phase 1 oncology trial; kidney safety signals remain a key concern.",
                "key_benefits": [
                    "Rapid fat-mass reduction in obese non-human primates",
                    "Improved insulin sensitivity",
                    "Direct WAT vascular targeting"
                ],
                "mechanism_of_action": "CKGGRAKDC homes to prohibitin/annexin A2 on white-fat endothelium; the linked D-(KLAKLAK)2 disrupts mitochondrial membranes after internalization, triggering localized endothelial apoptosis and adipocyte loss."
            },
            "research_indications": {
                "weight_loss": {
                    "effectiveness": "Most Effective",
                    "categories": [
                        {
                            "title": "Adipose Mass Reduction",
                            "description": "Selective WAT vascular targeting produced 7–15% body‑weight loss over 4 weeks in obese macaques."
                        }
                    ]
                },
                "metabolism": {
                    "effectiveness": "Effective",
                    "categories": [
                        {
                            "title": "Insulin Resistance",
                            "description": "Improved insulin response (reduced insulin AUC) following fat-mass reduction in primates."
                        }
                    ]
                },
                "appetite_control": {
                    "effectiveness": "Moderate",
                    "categories": [
                        {
                            "title": "Non-CNS Mechanism",
                            "description": "Weight loss without primary appetite suppression; peripheral (vascular) mechanism."
                        }
                    ]
                }
            },
            "research_protocols": [
                {
                    "goal": "Primate research replication",
                    "dose": "0.43 mg/kg",
                    "frequency": "Once daily",
                    "route": "Subcutaneous"
                },
                {
                    "goal": "Dose-finding (research)",
                    "dose": "0.10–0.75 mg/kg",
                    "frequency": "Once daily",
                    "route": "Subcutaneous (escalating tiers)"
                }
            ],
            "protocol_timing": "Rotate SC sites to reduce irritation; ensure adequate hydration and frequent renal labs during treatment.",
            "peptide_interactions": [
                {
                    "peptide": "Semaglutide (GLP-1 RA)",
                    "interaction": "Monitor Combination",
                    "description": "Potential additive dehydration/GI effects; monitor renal function."
                },
                {
                    "peptide": "Tirzepatide (GLP-1/GIP RA)",
                    "interaction": "Monitor Combination",
                    "description": "Overlapping weight-loss effects; monitor kidney function, volume status, and electrolytes."
                },
                {
                    "peptide": "Cagrilintide (Amylin analog)",
                    "interaction": "Unknown",
                    "description": "No clinical data on co-administration; mechanisms differ."
                },
                {
                    "peptide": "AOD-9604",
                    "interaction": "Unknown",
                    "description": "No published data on combined use or pharmacodynamic interaction."
                },
                {
                    "peptide": "BPC-157",
                    "interaction": "Compatible",
                    "description": "No known direct interaction; distinct mechanisms and targets."
                },
                {
                    "peptide": "CJC-1295 / Ipamorelin",
                    "interaction": "Use Caution",
                    "description": "Metabolic effects may confound body-composition endpoints; consider staging or separating protocols."
                },
                {
                    "peptide": "Melanotan II",
                    "interaction": "Requires Timing",
                    "description": "Theoretical vascular/pressor effects; stagger dosing if studied together."
                },
                {
                    "peptide": "Nephrotoxic drugs (NSAIDs, aminoglycosides)",
                    "interaction": "Avoid Combination",
                    "description": "Adipotide shows dose-dependent proximal tubule injury in primates; avoid additional renal insults."
                }
            ],
            "reconstitution_steps": [
                {
                    "step": 1,
                    "instruction": "Sanitize hands and workspace; swab vial septum."
                },
                {
                    "step": 2,
                    "instruction": "Inject BAC water slowly down the vial wall; do not jet onto powder."
                },
                {
                    "step": 3,
                    "instruction": "Gently swirl until fully dissolved (do not shake)."
                },
                {
                    "step": 4,
                    "instruction": "Label with concentration/date; store at 2–8°C; discard per lab SOP."
                }
            ],
            "quality_indicators": {
                "positive": [
                    {
                        "indicator": "Intact Lyophilized Cake",
                        "description": "White, uniform ‘cake’ indicates proper lyophilization."
                    },
                    {
                        "indicator": "Clear Solution",
                        "description": "Fully dissolved, particle-free solution after reconstitution."
                    }
                ],
                "negative": [
                    {
                        "indicator": "Collapsed/Moist Cake",
                        "description": "Suggests temperature excursion; do not use without QC."
                    },
                    {
                        "indicator": "Cloudiness/Precipitate",
                        "description": "Indicates degradation or contamination—discard per SOP."
                    }
                ]
            },
            "what_to_expect": [
                "Week 1–2: Early reduction in abdominal circumference",
                "Week 2–4: Progressive weight/fat-mass decline",
                "Recovery: Partial rebound possible after discontinuation",
                "Common lab signals: mild creatinine rise, electrolyte shifts"
            ],
            "side_effects_and_safety": [
                "Not FDA-approved; investigational/educational only.",
                "Monitor serum creatinine, BUN, urinalysis, electrolytes weekly in animal studies.",
                "Kidney: dose-dependent, largely reversible proximal tubule changes observed in primates.",
                "Avoid dehydration; consider temporarily pausing if creatinine rises persistently.",
                "Pregnancy/lactation: not studied; avoid."
            ],
            "references": [
                {
                    "title": "Obese rhesus macaques – fixed-dose efficacy & safety (2011)",
                    "type": "Primate study",
                    "dose_info": "0.43 mg/kg SC daily",
                    "duration": "28 days + 28-day recovery",
                    "findings": "7.4–14.7% weight loss; insulin resistance improved; mild, dose-dependent, reversible proximal tubule changes.",
                    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3666164/"
                },
                {
                    "title": "Rhesus macaques – dose-finding (2011)",
                    "type": "Primate study",
                    "dose_info": "0.10 → 0.25 → 0.43 → 0.75 mg/kg SC (escalated)",
                    "duration": "63 days total",
                    "findings": "Dose-dependent efficacy; renal safety signal >0.25 mg/kg.",
                    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3666164/"
                },
                {
                    "title": "Rodent proof-of-concept – targeted adipose vascular ablation (2004)",
                    "type": "Animal study",
                    "dose_info": "CKGGRAKDC-GG-D(KLAKLAK)2 daily",
                    "duration": "4 weeks",
                    "findings": "~30% weight reduction; adipose vascular apoptosis; metabolic normalization.",
                    "url": "https://pubmed.ncbi.nlm.nih.gov/15133506/"
                },
                {
                    "title": "First-in-human Phase 1 (oncology/weight) – terminated (2010–2013)",
                    "type": "Human trial (terminated)",
                    "dose_info": "Subcutaneous, dose-escalation",
                    "findings": "Early termination; limited enrollment.",
                    "url": "https://clinicaltrials.gov/study/NCT01262664"
                },
                {
                    "title": "Human adipose targeting – imaging validation (2018)",
                    "type": "Translational/Imaging",
                    "dose_info": "CKGGRAKDC MRI probe",
                    "findings": "Specific WAT targeting demonstrated.",
                    "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0197477"
                }
            ],
            "quick_start_guide": {
                "typical_dose": "0.43 mg/kg",
                "how_often": "Once daily",
                "how_to_take": "Rotated abdominal SubQ sites",
                "best_timing": "Consistent daily timing; monitor hydration",
                "effects_timeline": "Fat loss visible by 2–4 weeks in primate models",
                "storage": "2–8°C",
                "cycle_length": "28 days",
                "break_between": "≥4 weeks"
            },
            "citations": [
                {
                    "title": "A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys",
                    "subtitle": "Science Translational Medicine, 3(108), 108ra112 (2011)",
                    "publication_link": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3666164/"
                },
                {
                    "title": "Reversal of obesity by targeted ablation of adipose tissue",
                    "subtitle": "Nature Medicine, 10(6), 625-632 (2004)",
                    "publication_link": "https://pubmed.ncbi.nlm.nih.gov/15133506/"
                },
                {
                    "title": "Comment on: A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys",
                    "subtitle": "Science Translational Medicine, 4(131), 131le2 (2012)",
                    "publication_link": "https://www.science.org/doi/pdf/10.1126/scitranslmed.3003760"
                },
                {
                    "title": "Prohibitin/annexin 2 interaction regulates fatty acid transport in adipose tissue",
                    "subtitle": "JCI Insight, 1(10), e86351 (2016)",
                    "publication_link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033886/"
                },
                {
                    "title": "Targeted Molecular Magnetic Resonance Imaging Detects Brown Adipose Tissue in Vivo Using a CKGGRAKDC Peptide Probe",
                    "subtitle": "PLOS ONE, 13(6), e0197477 (2018)",
                    "publication_link": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0197477"
                },
                {
                    "title": "Vascular‑targeted nanotherapy for obesity: unexpected passive targeting mechanism to obese fat for the enhancement of active drug delivery",
                    "subtitle": "Journal of Controlled Release, 163(2), 101-110 (2012)",
                    "publication_link": "https://www.sciencedirect.com/science/article/abs/pii/S016836591200658X"
                },
                {
                    "title": "Prohibitin ligands in cell death and survival: mode of action and therapeutic potential",
                    "subtitle": "Cell Chemical Biology (Chemistry & Biology), 20(3), 316-325 (2013)",
                    "publication_link": "https://www.cell.com/chemistry-biology/fulltext/S1074-5521(13)00052-7"
                },
                {
                    "title": "Mixed‑Chirality Prohibitin Peptide: D‑(RLARLAR)2 Enhances Stability and In Vivo Effects on Obesity",
                    "subtitle": "Journal of the American Chemical Society, 147(28), 24628-24642 (2025)",
                    "publication_link": "https://pubmed.ncbi.nlm.nih.gov/40591817/"
                },
                {
                    "title": "Adipose tissue‑targeting nanomedicines for obesity pharmacotherapy",
                    "subtitle": "Trends in Endocrinology & Metabolism, Online ahead of print (2025)",
                    "publication_link": "https://pubmed.ncbi.nlm.nih.gov/40234177/"
                },
                {
                    "title": "A First‑in‑Man, Phase 1 Evaluation of a Prohibitin‑Targeting Peptide 1 (PROHIBITIN‑TP01) in Patients with Advanced Prostate Cancer (NCT01262664)",
                    "subtitle": "ClinicalTrials.gov (2010)",
                    "publication_link": "https://clinicaltrials.gov/study/NCT01262664"
                }
            ]
        },
        {
            "name": "Ara 290 (Cibinetide)",
            "subtitle": "Tissue-Protective Peptide | Innate Repair Receptor Agonist",
            "status": "Emerging Research",
            "typical_dose": "1-8 mg",
            "typical_dose_frequency": "Once daily",
            "route_of_administration": [
              {
                "route": "Injectable (Subcutaneous)",
                "details": "Anterior thigh, abdomen"
              },
              {
                "route": "Intravenous",
                "details": "Clinical setting only"
              }
            ],
            "cycle": "28 days",
            "storage": {
              "temperature": "2–8°C",
              "condition": "Refrigerated"
            },
            "overview": {
              "what_is_it": "Ara 290 (Cibinetide) is an engineered 11-amino acid peptide derived from erythropoietin that activates the Innate Repair Receptor (IRR) to provide tissue-protective effects without stimulating red blood cell production. It has completed multiple Phase 2 clinical trials and holds FDA Orphan Drug status for several indications.",
              "key_benefits": [
                "Proven tissue protection",
                "Nerve regeneration",
                "Anti-inflammatory effects",
                "Excellent safety profile in clinical trials"
              ],
              "mechanism_of_action": "Activates Innate Repair Receptor (IRR) through EPOR/β-common receptor complex, triggering tissue-protective signaling without erythropoietic effects"
            },
            "research_indications": {
              "neuroprotection": {
                "effectiveness": "Most Effective",
                "categories": [
                  {
                    "title": "Peripheral Nerve Regeneration",
                    "description": "23% increase in corneal nerve fiber area demonstrated in clinical trials, with sustained improvement in neuropathic pain"
                  },
                  {
                    "title": "Diabetic Neuropathy Treatment",
                    "description": "Significant nerve regeneration and metabolic improvements in Type 2 diabetes patients with peripheral neuropathy"
                  },
                  {
                    "title": "Central Nervous System Protection",
                    "description": "Crosses blood-brain barrier to provide neuroprotection in stroke and traumatic brain injury models"
                  }
                ]
              },
              "tissue_repair": {
                "effectiveness": "Effective",
                "categories": [
                  {
                    "title": "Wound Healing Enhancement",
                    "description": "Improves re-epithelialization and angiogenesis in diabetic wound models through VEGF upregulation"
                  },
                  {
                    "title": "Cardiovascular Protection",
                    "description": "Reduces infarct size and improves survival in myocardial infarction models with sustained cardioprotective effects"
                  },
                  {
                    "title": "Anti-Aging Tissue Effects",
                    "description": "Maintains cardiac function and reduces inflammation in aging heart models through IRR activation"
                  }
                ]
              },
              "anti_inflammatory": {
                "effectiveness": "Moderate",
                "categories": [
                  {
                    "title": "Cytokine Reduction",
                    "description": "Significantly reduces TNF-α, IL-6, and IL-12 production while maintaining tissue-protective signaling"
                  },
                  {
                    "title": "Inflammatory Bowel Disease",
                    "description": "Reduces colitis severity in animal models through broad anti-inflammatory mechanisms"
                  },
                  {
                    "title": "Transplant Protection",
                    "description": "Improves islet graft survival and reduces rejection through immunomodulatory effects"
                  }
                ]
              }
            },
            "research_protocols": [
              {
                "goal": "Neuropathy Treatment",
                "dose": "4 mg daily",
                "frequency": "Once daily",
                "route": "Subcutaneous"
              },
              {
                "goal": "Tissue Protection",
                "dose": "1-8 mg daily",
                "frequency": "Once daily",
                "route": "Subcutaneous"
              },
              {
                "goal": "Acute Intervention",
                "dose": "2 mg",
                "frequency": "3x weekly",
                "route": "Intravenous"
              },
              {
                "goal": "Research Protocol",
                "dose": "4 mg daily",
                "frequency": "Once daily for 28 days",
                "route": "Subcutaneous"
              }
            ],
            "protocol_timing": "Ara 290 has a short half-life (~20 minutes) but triggers long-lasting cellular effects. Morning administration may optimize circadian alignment with tissue repair processes.",
            "peptide_interactions": [
              {
                "peptide": "BPC-157",
                "interaction": "Synergistic",
                "description": "Both peptides promote tissue repair through complementary pathways - Ara 290 via IRR activation and BPC-157 via growth factor signaling, potentially enhancing wound healing and neuroprotection"
              },
              {
                "peptide": "TB-500",
                "interaction": "Synergistic",
                "description": "Combined tissue repair mechanisms may enhance recovery from injury - Ara 290 provides anti-inflammatory effects while TB-500 promotes cellular migration and angiogenesis"
              },
              {
                "peptide": "Thymosin Beta-4",
                "interaction": "Compatible",
                "description": "No known interactions between IRR activation and thymosin pathways, both work through different mechanisms for tissue protection and repair"
              },
              {
                "peptide": "EPO (Erythropoietin)",
                "interaction": "Avoid Combination",
                "description": "Clinical trials exclude recent EPO use within 2 months due to potential receptor interference and unclear combined effects on hematopoiesis"
              },
              {
                "peptide": "NAD+",
                "interaction": "Monitor Combination",
                "description": "Both affect cellular metabolism and stress response - monitor for additive anti-inflammatory effects and potential enhanced tissue protection"
              },
              {
                "peptide": "Semaglutide",
                "interaction": "Compatible",
                "description": "Clinical trials included patients on antidiabetic medications including GLP-1 agonists with no adverse interactions, may provide complementary metabolic benefits"
              },
              {
                "peptide": "Growth Hormone",
                "interaction": "Use Caution",
                "description": "Both affect tissue repair and growth pathways - combination may enhance effects but requires monitoring for potential excessive growth factor activity"
              },
              {
                "peptide": "Anti-TNF Biologics",
                "interaction": "Requires Timing",
                "description": "Clinical protocols require 6-month washout from anti-TNF therapy before Ara 290 to avoid potential immune system interactions"
              }
            ],
            "reconstitution_steps": [
              {
                "step": 1,
                "instruction": "Allow vial to reach room temperature (15-20 minutes)"
              },
              {
                "step": 2,
                "instruction": "Clean vial top with alcohol swab"
              },
              {
                "step": 3,
                "instruction": "Slowly inject 1 mL sterile water into vial"
              },
              {
                "step": 4,
                "instruction": "Gently swirl to dissolve (do not shake vigorously)"
              },
              {
                "step": 5,
                "instruction": "Solution may appear slightly cloudy - this is normal"
              },
              {
                "step": 6,
                "instruction": "Use immediately or store at 2-8°C for up to 24 hours"
              },
              {
                "step": 7,
                "instruction": "Protect from light during storage and use"
              },
              {
                "step": 8,
                "instruction": "Rotate injection sites (anterior thigh recommended)"
              }
            ],
            "quality_indicators": {
              "positive": [
                {
                  "indicator": "Pharmaceutical grade manufacturing",
                  "description": "Clinical trial material manufactured under GMP conditions with full quality documentation"
                },
                {
                  "indicator": "Proper peptide sequence verification",
                  "description": "Correct 11-amino acid sequence (pGlu-Glu-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser) with N-terminal pyroglutamate"
                },
                {
                  "indicator": "Sterile lyophilized powder",
                  "description": "Proper freeze-drying with excipients like sucrose or mannitol for stability and sterility"
                },
                {
                  "indicator": "Clinical batch documentation",
                  "description": "Certificates of analysis showing purity >95%, endotoxin levels <1 EU/mg, and sterility testing"
                }
              ],
              "negative": [
                {
                  "indicator": "Light-sensitive formulation",
                  "description": "Requires protection from light during storage, reconstitution, and administration"
                },
                {
                  "indicator": "Cloudy or discolored solution",
                  "description": "Reconstituted solution should be clear to slightly cloudy and colorless - discoloration indicates degradation"
                }
              ]
            },
            "what_to_expect": [
              "Week 1-2: Initial anti-inflammatory effects, potential mild improvement in pain symptoms",
              "Week 2-4: Progressive nerve regeneration, improved tissue healing markers, enhanced wound healing if applicable",
              "Week 4-6: Peak therapeutic effects, maximum nerve fiber density improvements, sustained pain relief",
              "Month 2-6: Long-lasting benefits continue due to molecular switch effect, sustained tissue protection"
            ],
            "side_effects_and_safety": [
              "Excellent safety profile in clinical trials with no serious drug-related adverse events",
              "No anti-drug antibodies detected in human studies",
              "No hematopoietic effects or risk of polycythemia unlike erythropoietin",
              "Contraindicated with recent anti-TNF therapy (within 6 months) or EPO use (within 2 months)",
              "Monitor for injection site reactions and rotate injection sites",
              "Not recommended during pregnancy or in patients with BMI >34 kg/m²"
            ],
            "references": [
              {
                "title": "Sarcoidosis Neuropathy Phase 2b Trial (2017)",
                "type": "Human Clinical Trial",
                "dose_info": "1-8 mg SC daily",
                "duration": "28 days",
                "findings": "23% increase in corneal nerve fiber area at 4 mg dose",
                "description": "Double-blind, placebo-controlled trial in 64 patients with sarcoidosis-associated small fiber neuropathy. The 4 mg dose showed significant nerve regeneration and pain reduction in moderate-severe cases.",
                "url": "https://clinicaltrials.gov/study/NCT02039687"
              },
              {
                "title": "Type 2 Diabetes Neuropathy Phase 2 (2015)",
                "type": "Human Clinical Trial",
                "dose_info": "4 mg SC daily",
                "duration": "28 days",
                "findings": "Sustained HbA1c improvement and nerve regeneration",
                "description": "Randomized controlled trial in 48 patients with diabetic peripheral neuropathy demonstrating sustained metabolic improvements and comparable nerve regeneration to sarcoidosis studies.",
                "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365069/"
              },
              {
                "title": "Diabetic Macular Edema Pilot Study (2020)",
                "type": "Human Clinical Trial",
                "dose_info": "4 mg SC daily",
                "duration": "12 weeks",
                "findings": "Improved quality of life, variable visual outcomes",
                "description": "Open-label pilot study in 9 patients examining Ara 290 effects on diabetic macular edema, showing good safety profile and improved patient-reported outcomes.",
                "url": "https://doi.org/10.3390/jcm9072225"
              },
              {
                "title": "Myocardial Infarction Protection Study (2012)",
                "type": "Preclinical Study",
                "dose_info": "24 μg/kg IV",
                "duration": "Single dose",
                "findings": "Reduced infarct size and improved survival",
                "description": "Preclinical study demonstrating cardioprotective effects of Ara 290 in acute myocardial infarction model with significant reduction in cardiac damage.",
                "url": "https://doi.org/10.1016/j.biocel.2012.04.009"
              },
              {
                "title": "Stroke Neuroprotection Research (2011)",
                "type": "Preclinical Study",
                "dose_info": "300 μg/kg IV",
                "duration": "Single dose",
                "findings": "Reduced stroke volume and improved outcomes",
                "description": "Comprehensive study showing Ara 290 crosses blood-brain barrier and provides significant neuroprotection in stroke models through IRR activation.",
                "url": "https://doi.org/10.1161/STROKEAHA.110.607309"
              },
              {
                "title": "Pancreatic Islet Protection Study (2021)",
                "type": "In Vitro Study",
                "dose_info": "100 nM",
                "duration": "48 hours",
                "findings": "Improved viability and function",
                "description": "In vitro study of human pancreatic islets showing Ara 290 protection against inflammatory damage, supporting its potential in diabetes treatment and transplantation.",
                "url": "https://doi.org/10.1177/09636897211039739"
              }
            ],
            "citations": [
    {
      "title": "Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin",
      "subtitle": "Proceedings of the National Academy of Sciences, 105(31), 10925-10930 (2008)",
      "publication_link": "https://doi.org/10.1073/pnas.0805594105"
    },
    {
      "title": "ARA 290, a nonerythropoietic EPO analog, for treatment of patients with sarcoidosis and chronic neuropathic pain",
      "subtitle": "Molecular Medicine, 19(1), 334-345 (2013)",
      "publication_link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967126/"
    },
    {
      "title": "ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes",
      "subtitle": "Molecular Medicine, 20(1), 658-666 (2015)",
      "publication_link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365069/"
    },
    {
      "title": "Clinical efficacy of ARA 290 (cibinetide) in sarcoidosis-associated neuropathy",
      "subtitle": "Investigative Ophthalmology & Visual Science, 58(6), BIO52-BIO60 (2017)",
      "publication_link": "https://doi.org/10.1167/iovs.16-21291"
    },
    {
      "title": "Cibinetide for the treatment of diabetic macular edema: A randomized controlled pilot study",
      "subtitle": "Journal of Clinical Medicine, 9(7), 2225 (2020)",
      "publication_link": "https://doi.org/10.3390/jcm9072225"
    },
    {
      "title": "The erythropoietin-derived peptide ARA 290 reverses the effects of chronic stress on depressive-like behavior and neuroplasticity markers",
      "subtitle": "Frontiers in Pharmacology, 13, 896601 (2022)",
      "publication_link": "https://doi.org/10.3389/fphar.2022.896601"
    },
    {
      "title": "ARA 290 protects human isolated pancreatic islets against lipotoxicity via reducing ER stress",
      "subtitle": "Cell Transplantation, 30, 09636897211039739 (2021)",
      "publication_link": "https://doi.org/10.1177/09636897211039739"
    },
    {
      "title": "Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin",
      "subtitle": "Pharmacology & Therapeutics, 151, 32-40 (2015)",
      "publication_link": "https://doi.org/10.1016/j.pharmthera.2015.02.005"
    }
  ],
},
{
    "name": "BPC-157",
    "typical_dose": "250-500mcg",
    "typical_dose_frequency": "1-2x daily",
    "route_of_administration": [
      {
        "route": "Injectable",
        "details": "Subcutaneous injection near injury (belly, thigh, arm for localized healing)"
      }
    ],
    "cycle": "4-8 weeks",
    "storage": {
      "temperature": "2-6°C",
      "condition": "Refrigerated"
    },
    "overview": {
      "what_is_it": "BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. It's known for its remarkable healing properties and is extensively researched for tissue repair, inflammation reduction, and gastrointestinal protection.",
      "key_benefits": [
        "Accelerated healing of tendons, ligaments, muscles, bones, and localized tissue repair",
        "Superior bioavailability for targeted healing",
        "Anti-inflammatory effects"
      ],
      "mechanism_of_action": "Injectable BPC-157 provides direct tissue targeting and higher local concentrations. Promotes angiogenesis (formation of new blood vessels), enhances collagen synthesis, modulates growth factor expression, and provides localized protection against tissue damage."
    },
    "research_indications": {
      "wound_healing": {
        "effectiveness": "Most Effective",
        "categories": [
          {
            "title": "Tendon Healing",
            "description": "Accelerated tendon-to-bone healing and improved biomechanical properties in injury models. Most effective with localized injection."
          },
          {
            "title": "Muscle Recovery",
            "description": "Enhanced muscle healing and reduced recovery time following crush injuries and surgical procedures with direct tissue targeting."
          },
          {
            "title": "Angiogenesis",
            "description": "Promotes blood vessel formation and improves vascularization in healing tissues through localized delivery."
          }
        ]
      },
      "neurological": {
        "effectiveness": "Effective",
        "categories": [
          {
            "title": "Neuroprotection",
            "description": "Protective effects against various neurotoxic agents and ischemic brain injury models with systemic administration."
          },
          {
            "title": "Spinal Cord Injury",
            "description": "Improved functional recovery and reduced tissue damage in spinal cord injury studies via injection."
          },
          {
            "title": "Peripheral Nerves",
            "description": "Enhanced peripheral nerve regeneration and functional recovery after injury with localized treatment."
          }
        ]
      },
      "gastrointestinal": {
        "effectiveness": "Moderate",
        "categories": [
          {
            "title": "Systemic GI Protection",
            "description": "Injectable BPC-157 provides systemic gastrointestinal protection through circulation, though oral may be more targeted for GI issues."
          },
          {
            "title": "Ulcer Prevention",
            "description": "Studies show protective effects against stress-induced gastric ulcers through systemic anti-inflammatory mechanisms."
          },
          {
            "title": "Intestinal Barrier",
            "description": "Supports intestinal barrier function and reduces inflammatory markers through systemic circulation."
          }
        ]
      }
    },
    "research_protocols": [
      {
        "goal": "Tendon/Joint healing",
        "dose": "250-500mcg",
        "frequency": "1-2x daily",
        "route": "SubQ near injury"
      },
      {
        "goal": "Serious injury",
        "dose": "500-1000mcg",
        "frequency": "2x daily",
        "route": "SubQ near injury"
      },
      {
        "goal": "General healing",
        "dose": "250-500mcg",
        "frequency": "1-2x daily",
        "route": "SubQ or IM"
      },
      {
        "goal": "Maintenance",
        "dose": "250mcg",
        "frequency": "1x daily",
        "route": "SubQ"
      }
    ],
    "protocol_timing": "Injectable BPC-157 is most effective on empty stomach. For injury healing, inject as close to the injury site as possible. Rotate injection sites to prevent tissue irritation.",
    "peptide_interactions": [
      {
        "peptide": "TB-500",
        "interaction": "Synergistic",
        "description": "Complementary healing mechanisms, often used together"
      },
      {
        "peptide": "GHRP-6",
        "interaction": "Compatible",
        "description": "No known negative interactions"
      },
      {
        "peptide": "Ipamorelin",
        "interaction": "Synergistic",
        "description": "BPC-157 increases GH receptor expression, amplifying Ipamorelin's growth hormone benefits"
      },
      {
        "peptide": "CJC-1295",
        "interaction": "Synergistic",
        "description": "BPC-157 upregulates GH receptors, enhancing CJC-1295 effectiveness for tissue repair"
      },
      {
        "peptide": "Melanotan II",
        "interaction": "Compatible",
        "description": "No known interactions - different mechanisms of action and receptor targets"
      },
      {
        "peptide": "AOD-9604",
        "interaction": "Unknown",
        "description": "Interaction profile unclear"
      }
    ],
    "reconstitution_steps": [
      {
        "step": 1,
        "instruction": "Clean work area and hands thoroughly"
      },
      {
        "step": 2,
        "instruction": "Calculate required BAC water volume using calculator"
      },
      {
        "step": 3,
        "instruction": "Draw BAC water into syringe"
      },
      {
        "step": 4,
        "instruction": "Inject slowly down vial side (not directly onto powder)"
      },
      {
        "step": 5,
        "instruction": "Gently swirl until dissolved (never shake)"
      },
      {
        "step": 6,
        "instruction": "Store in refrigerator, use within 28 days"
      }
    ],
    "quality_indicators": {
      "positive": [
        {
          "indicator": "White, Fluffy Cake",
          "description": "Lyophilized powder should appear as a white, fluffy 'cake' that fills most of the vial bottom. This indicates proper freeze-drying."
        },
        {
          "indicator": "Clear Solution After Reconstitution",
          "description": "When properly mixed with BAC water, solution should be crystal clear with no particles or cloudiness."
        },
        {
          "indicator": "Slight Clumping",
          "description": "Small clumps that dissolve completely with gentle swirling are acceptable. Shipping can cause minor compaction."
        }
      ],
      "negative": [
        {
          "indicator": "Collapsed or Melted Appearance",
          "description": "If powder appears collapsed, melted, or stuck to vial sides, it may have been exposed to heat during shipping."
        },
        {
          "indicator": "Cloudy After Reconstitution",
          "description": "Persistent cloudiness, particles, or precipitates after gentle mixing indicate degraded or contaminated peptide."
        }
      ]
    },
    "what_to_expect": [
      "Week 1-2: Reduced inflammation and pain at injection site",
      "Week 2-4: Improved healing rate and tissue repair",
      "Week 4-8: Maximum localized healing benefits",
      "Side effects: Mild injection site redness or irritation",
      "Most effective for: Tendon, ligament, muscle injuries"
    ],
    "side_effects_and_safety": [
      "Use sterile injection technique to prevent infection",
      "Generally well tolerated with minimal systemic side effects",
      "May cause mild injection site reactions",
      "Consult doctor if on blood thinners due to angiogenesis effects",
      "Not recommended during pregnancy or breastfeeding"
    ],
    "references": [
      {
        "title": "Achilles Tendon Healing Study (2003)",
        "type": "Animal study",
        "dose_info": "10 μg/kg i.p. daily",
        "duration": "14 days",
        "sample_size": "n/a",
        "findings": "Significant improvement in tendon healing compared to controls, improved biomechanical properties, faster functional recovery, enhanced tendon-to-bone integration.",
        "url": "https://doi.org/10.1016/S0736-0266(03)00110-4"
      },
      {
        "title": "Muscle Healing Research (2006)",
        "type": "Animal study",
        "dose_info": "10 μg/kg i.p. daily",
        "duration": "28 days",
        "sample_size": "n/a",
        "findings": "Enhanced muscle regeneration, improved histological appearance, reduced inflammatory markers, restored muscle function.",
        "url": "https://doi.org/10.1002/jor.20089"
      },
      {
        "title": "Spinal Cord Injury Recovery (2019)",
        "type": "Animal study",
        "dose_info": "10 μg/kg i.p. daily",
        "duration": "30 days",
        "sample_size": "n/a",
        "findings": "Improved functional recovery and reduced tissue damage in spinal cord injury models.",
        "url": "https://doi.org/10.1186/s13018-019-1242-6"
      },
      {
        "title": "Gastric Ulcer Protection (2020)",
        "type": "Animal study",
        "dose_info": "Multiple routes tested",
        "duration": "Various durations",
        "sample_size": "n/a",
        "findings": "Comprehensive study showing BPC-157's protective effects against gastric ulcers through multiple mechanisms including cytoprotection and enhanced mucosal healing.",
        "url": "https://doi.org/10.5009/gnl18490"
      },
      {
        "title": "VEGF and Angiogenesis Study (2017)",
        "type": "In vitro and animal study",
        "dose_info": "Various concentrations",
        "duration": "n/a",
        "sample_size": "n/a",
        "findings": "Demonstrated BPC-157's pro-angiogenic effects through VEGFR2 activation and upregulation, explaining its wound healing and tissue repair mechanisms.",
        "url": "https://doi.org/10.1007/s00109-016-1488-y"
      },
      {
        "title": "Safety Evaluation Study (2020)",
        "type": "Preclinical safety study",
        "dose_info": "Up to 1000 μg/kg",
        "duration": "90 days",
        "sample_size": "Multiple species",
        "findings": "Comprehensive toxicology; no serious adverse effects at therapeutic doses, established safety profile.",
        "url": "https://doi.org/10.1016/j.yrtph.2020.104665"
      }
    ],
    "quick_start_guide": {
      "typical_dose": "250-500mcg",
      "how_often": "1-2x daily",
      "how_to_take": "SubQ belly, thigh, or arm (near injury for localized healing)",
      "best_timing": "Empty stomach preferred",
      "effects_timeline": "1-3 weeks for healing, 3-7 days for inflammation",
      "storage": "Fridge 2-6°C, use within 28 days",
      "cycle_length": "4-12 weeks",
      "break_between": "4+ weeks"
    },
    "citations": [
        {
          "title": "Jóźwiak, M., Bauer, M., Kamysz, W., Kleczkowska, P. (2025). Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals, 18(2), 185.",
          "publication_link": "https://doi.org/10.3390/ph18020185"
        },
        {
          "title": "Seiwerth, S., Milavic, M., Vukojevic, J., et al. (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology, 12, 627533.",
          "publication_link": "https://doi.org/10.3389/fphar.2021.627533"
        },
        {
          "title": "Hsieh, M.J., Liu, H.T., Wang, C.N., et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine, 95(3), 323-333.",
          "publication_link": "https://doi.org/10.1007/s00109-016-1488-y"
        },
        {
          "title": "Staresinic, M., Sebecic, B., Patrlj, L., et al. (2003). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research, 21(6), 976-983.",
          "publication_link": "https://doi.org/10.1016/S0736-0266(03)00110-4"
        },
        {
          "title": "Chang, C.H., Tsai, W.C., Lin, M.S., Hsu, Y.H., Pang, J.H. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774-780.",
          "publication_link": "https://doi.org/10.1152/japplphysiol.00945.2010"
        },
        {
          "title": "Staresinic, M., Petrovic, I., Novinscak, T., et al. (2006). Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. Journal of Orthopaedic Research, 24(5), 1109-1117.",
          "publication_link": "https://doi.org/10.1002/jor.20089"
        },
        {
          "title": "Sikiric, P., Seiwerth, S., Rucman, R., et al. (2011). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 17(16), 1612-1632.",
          "publication_link": "https://doi.org/10.2174/138161211796196954"
        },
        {
          "title": "Sikiric, P., Hahm, K.B., Blagaic, A.B., et al. (2020). Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection. Gut and Liver, 14(2), 153-167.",
          "publication_link": "https://doi.org/10.5009/gnl18490"
        },
        {
          "title": "He, L., Feng, D., Guo, H., et al. (2022). Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157. Frontiers in Pharmacology, 13, 1026182.",
          "publication_link": "https://doi.org/10.3389/fphar.2022.1026182"
        },
        {
          "title": "Vukojevic, J., Milavić, M., Perović, D., et al. (2022). Pentadecapeptide BPC 157 and the central nervous system. Neural Regeneration Research, 17(3), 482-487.",
          "publication_link": "https://doi.org/10.4103/1673-5374.320969"
        },
        {
          "title": "Perovic, D., Kolenc, D., Bilic, V., et al. (2019). Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. Journal of Orthopaedic Surgery and Research, 14(1), 199.",
          "publication_link": "https://doi.org/10.1186/s13018-019-1242-6"
        },
        {
          "title": "Xu, C., Sun, L., Ren, F., et al. (2020). Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology, 114, 104665.",
          "publication_link": "https://doi.org/10.1016/j.yrtph.2020.104665"
        }
      ]
  },
  {
    "name": "BPC-157",
    "typical_dose": "500mcg-2mg",
    "typical_dose_frequency": "1-2x daily",
    "route_of_administration": [
      {
        "route": "Oral",
        "details": "Oral capsules (take with water, preferably on empty stomach 30 minutes before meals)"
      }
    ],
    "cycle": "4-8 weeks (typical), up to 12 weeks",
    "storage": {
      "temperature": "Room temperature (capsules); cool, dry place",
      "condition": "Keep sealed, avoid heat/moisture/light"
    },
    "overview": {
      "what_is_it": "BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. It's known for healing properties and is extensively researched for tissue repair, inflammation reduction, and gastrointestinal protection.",
      "key_benefits": [
        "Superior gastrointestinal protection",
        "Systemic healing effects",
        "Convenient oral administration",
        "Particularly effective for digestive issues, ulcer prevention, and general wellness"
      ],
      "mechanism_of_action": "Remarkably stable in gastric acid. Oral administration provides direct GI protection and systemic healing via absorption. Promotes tissue repair by enhancing mucosal healing, reducing inflammation, and supporting angiogenesis."
    },
    "research_indications": {
      "gastrointestinal": {
        "effectiveness": "Most Effective",
        "categories": [
          {
            "title": "Ulcer Protection",
            "description": "Superior protective effects against gastric and duodenal ulcers through direct gastric contact and cytoprotective mechanisms."
          },
          {
            "title": "Intestinal Repair",
            "description": "Accelerated intestinal healing, reduced inflammatory markers in IBD models through direct mucosal contact."
          },
          {
            "title": "Mucosal Healing",
            "description": "Enhanced barrier function and accelerated epithelial regeneration via oral administration."
          }
        ]
      },
      "wound_healing": {
        "effectiveness": "Effective",
        "categories": [
          {
            "title": "Systemic Healing",
            "description": "Systemic healing effects through circulation support tissue repair and recovery."
          },
          {
            "title": "Anti-inflammatory",
            "description": "Systemic anti-inflammatory effects support healing throughout the body via oral absorption."
          },
          {
            "title": "Tissue Protection",
            "description": "General tissue protection and repair through systemic circulation; less targeted than injectable form."
          }
        ]
      },
      "neurological": {
        "effectiveness": "Moderate",
        "categories": [
          {
            "title": "Neuroprotection",
            "description": "Systemic neuroprotective effects, though may require higher doses than injectable."
          },
          {
            "title": "Cognitive Support",
            "description": "Potential support through gut-brain axis modulation."
          },
          {
            "title": "Stress Response",
            "description": "May aid stress modulation and neurological regulation via gut-brain connection."
          }
        ]
      }
    },
    "research_protocols": [
      {
        "goal": "Gastric protection",
        "dose": "500mcg-1mg",
        "frequency": "1-2x daily",
        "route": "Oral (empty stomach)"
      },
      {
        "goal": "General healing",
        "dose": "1-2mg",
        "frequency": "1-2x daily",
        "route": "Oral (empty stomach)"
      },
      {
        "goal": "Ulcer prevention",
        "dose": "500mcg",
        "frequency": "2x daily",
        "route": "Oral (empty stomach)"
      },
      {
        "goal": "Maintenance",
        "dose": "500mcg",
        "frequency": "1x daily",
        "route": "Oral (empty stomach)"
      }
    ],
    "protocol_timing": "Most effective on empty stomach, 30 minutes before meals. Take consistently at same times daily.",
    "peptide_interactions": [
      {
        "peptide": "TB-500",
        "interaction": "Synergistic",
        "description": "Complementary healing mechanisms, often used together."
      },
      {
        "peptide": "GHRP-6",
        "interaction": "Compatible",
        "description": "No known negative interactions."
      },
      {
        "peptide": "Ipamorelin",
        "interaction": "Synergistic",
        "description": "Increases GH receptor expression, amplifying growth hormone benefits."
      },
      {
        "peptide": "CJC-1295",
        "interaction": "Synergistic",
        "description": "Upregulates GH receptors, enhances CJC-1295 tissue repair."
      },
      {
        "peptide": "Melanotan II",
        "interaction": "Compatible",
        "description": "No known interactions – different mechanism."
      },
      {
        "peptide": "AOD-9604",
        "interaction": "Unknown",
        "description": "Profile unclear."
      }
    ],
    "reconstitution_steps": [
      {
        "step": 1,
        "instruction": "Use pre-made stable oral capsules (recommended for convenience)."
      },
      {
        "step": 2,
        "instruction": "If using powder: measure accurate dose with precision milligram scale."
      },
      {
        "step": 3,
        "instruction": "Fill empty capsules with powder if making your own."
      },
      {
        "step": 4,
        "instruction": "Take on empty stomach with water (30 min before meals)."
      },
      {
        "step": 5,
        "instruction": "Wait 30 minutes before eating for optimal absorption."
      },
      {
        "step": 6,
        "instruction": "Store capsules in cool, dry place at room temp."
      }
    ],
    "quality_indicators": {
      "positive": [
        {
          "indicator": "Intact Capsules",
          "description": "No cracks, discoloration or moisture. Clear dosage labeling."
        },
        {
          "indicator": "Proper Packaging",
          "description": "Sealed bottles or blister packs with expiration dates, batch numbers. Professional packaging."
        },
        {
          "indicator": "Fine Powder",
          "description": "If using powder, should be fine, white to off-white, no clumping/discoloration."
        }
      ],
      "negative": [
        {
          "indicator": "Moisture Damage",
          "description": "Capsules shouldn't be sticky/discolored. Powder should not be clumped."
        },
        {
          "indicator": "Poor Storage",
          "description": "Avoid products stored in excess heat, humidity, or light."
        }
      ]
    },
    "what_to_expect": [
      "Week 1-2: Improved digestive comfort, reduced GI irritation",
      "Week 2-4: Enhanced gastric protection and healing",
      "Week 4-8: Systemic healing benefits, overall wellness",
      "Side effects: Minimal, mild GI adjustment possible",
      "Most effective for: Gastric ulcers, digestive issues, general healing"
    ],
    "side_effects_and_safety": [
      "Generally very well tolerated",
      "Take on empty stomach for best absorption",
      "May cause mild digestive adjustment in first few days",
      "Consult doctor if on blood thinners",
      "Not recommended during pregnancy or breastfeeding"
    ],
    "references": [
      {
        "title": "Jóźwiak, M., Bauer, M., Kamysz, W., Kleczkowska, P. (2025). Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals, 18(2), 185.",
        "publication_link": "https://doi.org/10.3390/ph18020185"
      },
      {
        "title": "Seiwerth, S., Milavic, M., Vukojevic, J., et al. (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology, 12, 627533.",
        "publication_link": "https://doi.org/10.3389/fphar.2021.627533"
      },
      {
        "title": "Hsieh, M.J., Liu, H.T., Wang, C.N., et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine, 95(3), 323-333.",
        "publication_link": "https://doi.org/10.1007/s00109-016-1488-y"
      },
      {
        "title": "Staresinic, M., Sebecic, B., Patrlj, L., et al. (2003). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research, 21(6), 976-983.",
        "publication_link": "https://doi.org/10.1016/S0736-0266(03)00110-4"
      },
      {
        "title": "Chang, C.H., Tsai, W.C., Lin, M.S., Hsu, Y.H., Pang, J.H. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774-780.",
        "publication_link": "https://doi.org/10.1152/japplphysiol.00945.2010"
      },
      {
        "title": "Staresinic, M., Petrovic, I., Novinscak, T., et al. (2006). Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. Journal of Orthopaedic Research, 24(5), 1109-1117.",
        "publication_link": "https://doi.org/10.1002/jor.20089"
      },
      {
        "title": "Sikiric, P., Seiwerth, S., Rucman, R., et al. (2011). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 17(16), 1612-1632.",
        "publication_link": "https://doi.org/10.2174/138161211796196954"
      },
      {
        "title": "Sikiric, P., Hahm, K.B., Blagaic, A.B., et al. (2020). Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection. Gut and Liver, 14(2), 153-167.",
        "publication_link": "https://doi.org/10.5009/gnl18490"
      },
      {
        "title": "He, L., Feng, D., Guo, H., et al. (2022). Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157. Frontiers in Pharmacology, 13, 1026182.",
        "publication_link": "https://doi.org/10.3389/fphar.2022.1026182"
      },
      {
        "title": "Vukojevic, J., Milavić, M., Perović, D., et al. (2022). Pentadecapeptide BPC 157 and the central nervous system. Neural Regeneration Research, 17(3), 482-487.",
        "publication_link": "https://doi.org/10.4103/1673-5374.320969"
      },
      {
        "title": "Perovic, D., Kolenc, D., Bilic, V., et al. (2019). Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. Journal of Orthopaedic Surgery and Research, 14(1), 199.",
        "publication_link": "https://doi.org/10.1186/s13018-019-1242-6"
      },
      {
        "title": "Xu, C., Sun, L., Ren, F., et al. (2020). Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology, 114, 104665.",
        "publication_link": "https://doi.org/10.1016/j.yrtph.2020.104665"
      }
    ],
    "references": [
        {
          "title": "Achilles Tendon Healing Study (2003)",
          "type": "Animal study",
          "dose_info": "10 μg/kg i.p. daily",
          "duration": "14 days",
          "sample_size": "n/a",
          "findings": "Significant improvement in tendon healing compared to controls, improved biomechanical properties, faster functional recovery, enhanced tendon-to-bone integration.",
          "url": "https://doi.org/10.1016/S0736-0266(03)00110-4"
        },
        {
          "title": "Muscle Healing Research (2006)",
          "type": "Animal study",
          "dose_info": "10 μg/kg i.p. daily",
          "duration": "28 days",
          "sample_size": "n/a",
          "findings": "Enhanced muscle regeneration, improved histological appearance, reduced inflammatory markers, restored muscle function.",
          "url": "https://doi.org/10.1002/jor.20089"
        },
        {
          "title": "Spinal Cord Injury Recovery (2019)",
          "type": "Animal study",
          "dose_info": "10 μg/kg i.p. daily",
          "duration": "30 days",
          "sample_size": "n/a",
          "findings": "Improved functional recovery and reduced tissue damage in spinal cord injury models.",
          "url": "https://doi.org/10.1186/s13018-019-1242-6"
        },
        {
          "title": "Gastric Ulcer Protection (2020)",
          "type": "Animal study",
          "dose_info": "Multiple routes tested",
          "duration": "Various durations",
          "sample_size": "n/a",
          "findings": "Comprehensive study showing BPC-157's protective effects against gastric ulcers through multiple mechanisms including cytoprotection and enhanced mucosal healing.",
          "url": "https://doi.org/10.5009/gnl18490"
        },
        {
          "title": "VEGF and Angiogenesis Study (2017)",
          "type": "In vitro and animal study",
          "dose_info": "Various concentrations",
          "duration": "n/a",
          "sample_size": "n/a",
          "findings": "Demonstrated BPC-157's pro-angiogenic effects through VEGFR2 activation and upregulation, explaining its wound healing and tissue repair mechanisms.",
          "url": "https://doi.org/10.1007/s00109-016-1488-y"
        },
        {
          "title": "Safety Evaluation Study (2020)",
          "type": "Preclinical safety study",
          "dose_info": "Up to 1000 μg/kg",
          "duration": "90 days",
          "sample_size": "Multiple species",
          "findings": "Comprehensive toxicology; no serious adverse effects at therapeutic doses, established safety profile.",
          "url": "https://doi.org/10.1016/j.yrtph.2020.104665"
        }
      ],
    "quick_start_guide": {
      "typical_dose": "500mcg-1mg",
      "how_often": "1-2x daily",
      "how_to_take": "Oral capsules (with water, empty stomach)",
      "best_timing": "30 minutes before meals",
      "effects_timeline": "1-4 weeks for GI effects, 2-6 weeks for systemic healing",
      "storage": "Room temp, cool dry place",
      "cycle_length": "4-12 weeks",
      "break_between": "4+ weeks"
    }
  },
  {
    "name": "Cagrilintide",
    "typical_dose": "2.4 mg weekly",
    "typical_dose_frequency": "Once weekly",
    "route_of_administration": [
      {
        "route": "Injectable",
        "details": "Subcutaneous injection (abdomen, thigh, or upper arm; rotate weekly)"
      }
    ],
    "cycle": "Continuous (no defined endpoint in clinical trials)",
    "storage": {
      "temperature": "-20°C frozen; 2-8°C refrigerated after reconstitution",
      "condition": "Protect from light, avoid freeze-thaw cycles"
    },
    "overview": {
      "what_is_it": "Cagrilintide (AM833) is a novel long-acting lipidated amylin analog acting as a dual amylin and calcitonin receptor agonist, developed for weight management and type 2 diabetes treatment. Shows superior weight loss potential in combination with semaglutide (CagriSema).",
      "key_benefits": [
        "FDA development candidate, extensive Phase 3 data",
        "Superior weight loss in combination with semaglutide",
        "Once-weekly dosing convenience"
      ],
      "mechanism_of_action": "Subcutaneous injection provides optimal bioavailability for targeting dual amylin/calcitonin receptors, increasing satiety and improving metabolic outcomes."
    },
    "research_indications": {
      "weight_loss": {
        "effectiveness": "Most Effective",
        "categories": [
          {
            "title": "Superior Obesity Treatment",
            "description": "Phase 3 trials demonstrate up to 22.7% weight loss with CagriSema (cagrilintide + semaglutide) combination."
          },
          {
            "title": "Type 2 Diabetes Weight Management",
            "description": "15.7% weight loss in diabetic patients supported by glycemic improvements."
          },
          {
            "title": "Sustained Weight Maintenance",
            "description": "Long-acting formulation supports durable weight loss throughout treatment."
          }
        ]
      },
      "metabolic": {
        "effectiveness": "Effective",
        "categories": [
          {
            "title": "Glucose Control Enhancement",
            "description": "Phase 2 data shows 2.2% HbA1c reduction with CagriSema."
          },
          {
            "title": "Insulin Sensitivity",
            "description": "Amylin receptor activation increases insulin sensitivity and supports glucose metabolism."
          },
          {
            "title": "Gastric Emptying Regulation",
            "description": "Controlled gastric emptying improves postprandial glucose and satiety."
          }
        ]
      },
      "appetite_control": {
        "effectiveness": "Moderate",
        "categories": [
          {
            "title": "Dual Pathway Satiety",
            "description": "Amylin/calcitonin receptor activation offers robust appetite suppression."
          },
          {
            "title": "Food Preference Modulation",
            "description": "Central pathways influence eating behaviors and preferences."
          },
          {
            "title": "Early Satiation",
            "description": "Promotes fullness with smaller meal portions."
          }
        ]
      }
    },
    "research_protocols": [
      {
        "goal": "Weight Loss (Monotherapy)",
        "dose": "2.4 mg weekly",
        "frequency": "Once weekly",
        "route": "Subcutaneous"
      },
      {
        "goal": "Weight Loss (CagriSema)",
        "dose": "2.4 mg + semaglutide 2.4 mg weekly",
        "frequency": "Once weekly",
        "route": "Subcutaneous"
      },
      {
        "goal": "Type 2 Diabetes Management",
        "dose": "2.4 mg weekly",
        "frequency": "Once weekly",
        "route": "Subcutaneous with metformin"
      },
      {
        "goal": "Dose Escalation Protocol",
        "dose": "0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg",
        "frequency": "Weekly increase over 16 weeks",
        "route": "Subcutaneous"
      },
      {
        "goal": "Combination Diabetes Therapy",
        "dose": "2.4 mg + SGLT2 inhibitor weekly",
        "frequency": "Once weekly",
        "route": "Subcutaneous"
      },
      {
        "goal": "Cardiovascular Risk Reduction",
        "dose": "2.4 mg weekly",
        "frequency": "Once weekly",
        "route": "Subcutaneous (REDEFINE 3 trial)"
      }
    ],
    "protocol_timing": "Administer on the same day each week; evening injection may reduce nausea. Can be given with or without food.",
    "peptide_interactions": [
      {
        "peptide": "Semaglutide",
        "interaction": "Synergistic",
        "description": "CagriSema provides enhanced weight loss and improved glycemic control (amylin + GLP-1 pathways)."
      },
      {
        "peptide": "Tirzepatide",
        "interaction": "Compatible",
        "description": "No direct interactions; different mechanisms, theoretical potential for synergy."
      },
      {
        "peptide": "Retatrutide",
        "interaction": "Unknown",
        "description": "No studies; both achieve similar weight loss through different mechanisms."
      },
      {
        "peptide": "Liraglutide",
        "interaction": "Compatible",
        "description": "Similar efficacy, no adverse interactions reported."
      },
      {
        "peptide": "Insulin",
        "interaction": "Monitor Combination",
        "description": "Can affect gastric emptying and insulin absorption; may require dose adjustments."
      },
      {
        "peptide": "Metformin",
        "interaction": "Compatible",
        "description": "No pharmacokinetic interactions, tolerated in trials."
      },
      {
        "peptide": "SGLT2 Inhibitors",
        "interaction": "Compatible",
        "description": "Used safely in trials for diabetes and weight management."
      },
      {
        "peptide": "Pramlintide",
        "interaction": "Avoid Combination",
        "description": "Both are amylin receptor agonists; overlapping mechanisms and risk of GI side effects."
      },
      {
        "peptide": "Oral Contraceptives",
        "interaction": "Requires Timing",
        "description": "Delayed gastric emptying may impact absorption; space administration by 1 hour."
      }
    ],
    "reconstitution_steps": [
      {
        "step": 1,
        "instruction": "Use bacteriostatic water (BAC), sterile technique essential."
      },
      {
        "step": 2,
        "instruction": "Acidify BAC to pH 3.5–4.5 for optimal stability. Standard BAC (pH 5.5–6) is acceptable short-term (<30 days)."
      },
      {
        "step": 3,
        "instruction": "Slowly reconstitute down vial side, swirl gently."
      },
      {
        "step": 4,
        "instruction": "Verify solution clarity; discard if cloudy or particulate."
      },
      {
        "step": 5,
        "instruction": "Store refrigerated (2–8°C) after reconstitution."
      },
      {
        "step": 6,
        "instruction": "Allow vial to reach room temperature before injection."
      }
    ],
    "quality_indicators": {
      "positive": [
        {
          "indicator": "Pre-filled pen design",
          "description": "Clinical and future pharmaceutical forms are convenient, stable."
        },
        {
          "indicator": "Pharmaceutical grade purity",
          "description": "Clinical trial material is >98% pure, properly lipidated."
        },
        {
          "indicator": "Frozen storage stability",
          "description": "Stability maintained at -20°C."
        },
        {
          "indicator": "Extended stability profile",
          "description": "Remains stable >7 days at dosing interval."
        }
      ],
      "negative": [
        {
          "indicator": "Fibril formation at improper pH",
          "description": "Cloudy, gel-like texture signals degradation. Discard."
        },
        {
          "indicator": "Aggregation or precipitation",
          "description": "Visible particles or color changes signal protein degradation."
        },
        {
          "indicator": "Temperature excursions",
          "description": "High temperatures, freeze-thaw cycles are harmful."
        }
      ]
    },
    "what_to_expect": [
      "Week 1-2: GI adaptation or mild nausea, dose escalation phase",
      "Week 4-8: Early weight loss, increased satiety",
      "Week 12-26: Significant weight loss, peak effects",
      "Week 26+: Sustained maintenance with ongoing therapy"
    ],
    "side_effects_and_safety": [
      "Most side effects are GI-related (nausea, vomiting, diarrhea) in initial weeks",
      "Anti-cagrilintide antibodies develop in 46–73% of patients, but efficacy unchanged",
      "No clinically relevant QTc prolongation",
      "Only 57.3% of patients reach full 2.4 mg in REDEFINE 1 trial",
      "Acidic reconstitution required to avoid degradation"
    ],
    "references": [
      {
        "title": "REDEFINE 1 Trial - Phase 3 Weight Loss (2025)",
        "summary": "Humans | 2.4 mg weekly | 68 weeks | 22.7% weight loss vs 2.4% placebo",
        "full_info": "Landmark Phase 3 trial published in NEJM demonstrating superior weight loss with CagriSema combination in 3,417 adults with obesity, achieving primary endpoints with excellent safety profile",
        "publication_link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2502081"
      },
      {
        "title": "REDEFINE 2 Trial - Phase 3 Type 2 Diabetes (2025)",
        "summary": "Humans | 2.4 mg weekly | 68 weeks | 15.7% weight loss, 73.5% achieved HbA1c ≤6.5%",
        "full_info": "Phase 3 trial in 1,206 adults with type 2 diabetes and obesity published in NEJM, demonstrating significant weight loss and glycemic improvements with CagriSema",
        "publication_link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2502082"
      },
      {
        "title": "Phase 2 Type 2 Diabetes Combination Study (2023)",
        "summary": "Humans | 2.4 mg weekly | 32 weeks | 15.6% weight loss, 2.2% HbA1c reduction with CagriSema",
        "full_info": "First study reporting efficacy of GLP-1/amylin combination in type 2 diabetes, showing superior weight loss and glycemic control versus individual components",
        "publication_link": "https://www.sciencedirect.com/science/article/abs/pii/S0140673623011637"
      },
      {
        "title": "Phase 2 Dose-Finding Monotherapy Trial (2021)",
        "summary": "Humans | 0.3-4.5 mg weekly | 26 weeks | Up to 10.8% weight loss dose-dependent",
        "full_info": "Multi-center dose-finding trial in 706 participants demonstrating dose-dependent weight loss and establishing optimal 2.4 mg weekly dosing",
        "publication_link": "https://pubmed.ncbi.nlm.nih.gov/34798060/"
      },
      {
        "title": "Phase 1b Safety and Pharmacokinetics Study (2021)",
        "summary": "Humans | 0.16-4.5 mg weekly | 20 weeks | Safety profile established",
        "full_info": "First-in-human combination study with semaglutide demonstrating acceptable safety profile and pharmacokinetic parameters for CagriSema development",
        "publication_link": "https://www.sciencedirect.com/science/article/abs/pii/S014067362100845X"
      },
      {
        "title": "Thorough QT Study - Cardiac Safety (2024)",
        "summary": "Humans | 4.5 mg single dose | 5 days | No clinically relevant QTc prolongation",
        "full_info": "Dedicated cardiac safety study confirming no significant QT interval prolongation at supratherapeutic doses, supporting cardiovascular safety profile",
        "publication_link": "https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.15951"
      }
    ],
    "quick_start_guide": {
      "typical_dose": "2.4 mg weekly (after escalation)",
      "how_often": "Once weekly",
      "how_to_take": "Subcutaneous injection",
      "best_timing": "Same day weekly, preferably evening",
      "effects_timeline": "Initial effects: 1–2 weeks; Significant: 4–12 weeks; Peak: 26+ weeks",
      "storage": "Frozen -20°C (unmixed), 2–8°C (mixed)",
      "cycle_length": "Continuous for sustained effects",
      "break_between": "Not applicable (continuous therapy)"
    },
  "citations": [
    {
      "title": "Garvey, W.T., Blüher, M., Contreras, C.K.O., et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 393(1), 26-40. DOI: 10.1056/NEJMoa2502081",
      "publication_link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2502081"
    },
    {
      "title": "Davies, M.J., Bajaj, H.S., Broholm, C., et al. (2025). Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine, 393(1), 41-53. DOI: 10.1056/NEJMoa2502082",
      "publication_link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2502082"
    },
    {
      "title": "Frias, J.P., Auerbach, P., Bajaj, H.S., et al. (2023). Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. The Lancet, 402(10401), 720-730. DOI: 10.1016/S0140-6736(23)01163-7",
      "publication_link": "https://www.sciencedirect.com/science/article/abs/pii/S0140673623011637"
    },
    {
      "title": "Lau, D.C.W., Erichsen, L., Francisco, A.M., et al. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet, 398(10317), 2160-2172. DOI: 10.1016/S0140-6736(21)01751-7",
      "publication_link": "https://pubmed.ncbi.nlm.nih.gov/34798060/"
    },
    {
      "title": "Enebo, L.B., Berthelsen, K.K., Kankam, M., et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. The Lancet, 397(10286), 1736-1748. DOI: 10.1016/S0140-6736(21)00845-X",
      "publication_link": "https://www.sciencedirect.com/science/article/abs/pii/S014067362100845X"
    },
    {
      "title": "Kruse, T., Glastrup, S., Moser, C., et al. (2021). Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry, 64(16), 11183-11194. DOI: 10.1021/acs.jmedchem.1c00565",
      "publication_link": "https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00565"
    },
    {
      "title": "Cao, J., Gholamrezaie, L., Donnelly, D., et al. (2025). Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature Communications, 16, 850. DOI: 10.1038/s41467-025-58680-y",
      "publication_link": "https://www.nature.com/articles/s41467-025-58680-y"
    },
    {
      "title": "Gabe, M.B.N., Sonne, N., Liu, L., et al. (2024). Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants. Diabetes, Obesity and Metabolism, 26(11), 4985-4994. DOI: 10.1111/dom.15951",
      "publication_link": "https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.15951"
    },
    {
      "title": "Dutta, D., Nagendra, L., Harish, B.G., et al. (2024). Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis. Indian Journal of Endocrinology and Metabolism, 28(5), 436-444. DOI: 10.4103/ijem.ijem_45_24",
      "publication_link": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11642503/"
    },
    {
      "title": "D'Ascanio, A.M., Mullally, J.A., Frishman, W.H. (2024). Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Cardiology in Review, 32(1), 83-90. DOI: 10.1097/CRD.0000000000000513",
      "publication_link": "https://journals.lww.com/cardiologyinreview/fulltext/2024/01000/cagrilintide__a_long_acting_amylin_analog_for_the.13.aspx"
    }
  ]
  },
  
  
  
  

          

    ]